VAMG
MRNA icon

Voisard Asset Management Group’s Moderna MRNA Stock Holding History

Voisard Asset Management Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$335 – 440
2024
Q3 		$335 Buy
+5
New +$459 ﹤0.01% 674

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Voisard Asset Management Group's MRNA Position: Q4 2024 in Review

Voisard Asset Management Group sold out of Moderna (MRNA) in Q4 2024, closing a stake of 5 shares — an estimated $335 sold.

Voisard Asset Management Group first reported a position in MRNA in Q3 2024 and held it in 1 quarter. The position peaked at $335 in Q3 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Voisard Asset Management Group reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Voisard Asset Management Group sold 5 Moderna shares in Q4 2024, an estimated $335.
  • Voisard Asset Management Group first reported a position in Moderna in Q3 2024 and held it in 1 quarter.
  • Voisard Asset Management Group's Moderna position peaked at $335 in Q3 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Voisard Asset Management Group's 13F filing for Q4 2024, filed 7 Feb 2025.